A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
Recruiting now · Not applicable
Conditions studied: Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
In brief
This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before surgery (neoadjuvant). Pancreatic cancer is a rare and understudied cancer, particularly in the area of promoting a healthy lifestyle to preserve physical and mental well-being during a long and difficult treatment regimen. Since pancreatic cancer is rare, programs have limited resources available to reach the patients who could benefit from programs aimed at promoting exercise and a healthy diet. The COMPASS web-portal is easily accessed by the patient via a computer, tablet, or phone. It is tailored to the unique needs of pancreatic cancer patients and provides exercise and diet recommendations along with behavioral support as they undergo the long process of cancer therapy. This may be a more effective way to reach and engage with the patient, which may improve exercise and dietary changes in stage I-III pancreatic cancer patients receiving neoadjuvant chemotherapy.
Key facts
- Study ID
- NCT07651358
- Run by
- OHSU Knight Cancer Institute
- People needed
- 30
- Starts
- 2026-04-15
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 years or older on date of enrollment
- Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)
- Diagnosed with stage I-III pancreatic cancer
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
- Scheduled to receive neoadjuvant chemotherapy at Oregon Health \& Science University (OHSU)
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
- Willing to adhere to the study protocol
- Confirmed verbally with the participant and response documented in the Participant Tracking database
You may not qualify if…
- Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent
- In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and/or Dr. Jackilen Shannon
- A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise
- Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible
- Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English
- Confirmed verbally with the participant and response documented in the Participant Tracking database
Where it is running
- OHSU Knight Cancer Institute — Portland, Oregon, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.